Management

Mr Kay joined Algeta as President and CEO in 2009. He has more than 25 years of global commercial and development experience within the pharmaceutical industry and has launched major oncology and other pharmaceutical drugs. Prior to joining Algeta, Mr Kay was Executive Director Commercial at Renovo Group Plc, a UK-listed pharmaceutical company. Before that , he held the roles of Head of Global Marketing and Sales for Novartis, where he was also a member of the Pharmaceutical Executive Board in Basel, Switzerland; Head of Business Management and Country Management at AstraZeneca; Head of Global Marketing at Zeneca; Head of Zeneca Diagnostics; Vice President Marketing, Zeneca USA; Marketing Manager and Deputy General Manager, Stuart UK; and International Brand Manager with Eli Lilly in Italy. He is a British citizen and resides in the UK.

As of 12 April 2013, Mr Kay holds no shares and 660,000 share options in Algeta.

Dr Ramdahl is a pharmaceutical executive with almost 20 years of clinical and development experience. He joined Algeta in 2001 as CEO and remained in this role until 2009, when he became CTO. Before that, between 1998 and 2001, he was Senior Vice President, Operations at Pronova Biocare AS, where he headed all operation functions including raw material sourcing and manufacturing of bulk products, nutritional supplements, and pharmaceutical products. Prior to Pronova, Dr Ramdahl held several senior executive positions within the pharmaceutical, oil and gas, and petrochemical divisions of Norsk Hydro ASA. He has authored more than 40 publications, and is a co-inventor of several patents. Dr Ramdahl gained a PhD in Environmental Chemistry from the University of Oslo (1984) and an MSc in Organic Chemistry from the Norwegian Institute of Technology (1979). He has also been engaged in executive training at IMD in Lausanne, Switzerland. He is a Norwegian citizen and resides in Norway.

As of 12 April 2013, Dr Ramdahl holds 20,200 shares and 238,337 share options in Algeta.

Mr Albers joined Algeta in January 2012 bringing significant commercial and corporate development experience within the pharmaceutical industry. Prior to joining Algeta, he spent seven years at Genzyme (Sanofi), where as Vice President, US Hematology & Oncology Business, he managed the  US business that included multiple marketed products as well as a pipeline of products for hematologic and solid tumor malignancies. In this role, he helped build and lead a team comprising sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. While in corporate development, Mr Albers identified and led a variety of licensing, partnering and M&A transactions and also managed Genzyme Ventures. Prior to Genzyme, Mr Albers was an attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work, and before that was a sales representative for Pfizer Inc. Mr Albers has a BSc in Marketing from Indiana University, and a law degree (JD) and MBA from Georgetown University. He is a US citizen and resides in the US.

As of 12 April 2013, Mr Albers holds no shares and 245,000 share options in Algeta.

.

Dr Booth joined Algeta in 2011. He has more than 12 years’ experience in communications, investor relations, and the capital markets, having worked in investment banking, equity research, and investor relations consulting positions for the biotechnology and life sciences industry. Prior to joining Algeta, Dr Booth was responsible for setting up and running Trout International LLC, the European business of The Trout Group LLC. Before joining The Trout Group, Dr Booth worked for UBS, Bank of America, and Canaccord Adams as an equity analyst focused on the biotechnology sector. Dr Booth received his DPhil from the University of Oxford studying the neurophysiology of vision, learning, and memory, and was awarded a first class degree in Psychology from the University of St Andrews in Scotland. He is a British citizen and resides in the UK.

As of 12 April 2013, Dr Booth holds no shares and 195,000 share options in Algeta.

Dr Cuthbertson joined Algeta in November 2012 as SVP R&D. He has more than 20 years of experience in discovery R&D, medicinal chemistry and product development. He gained most of his experience at GE Healthcare and was most recently in a senior management role within the company’s Discovery R&D organization. His responsibilities included translation of new contrast media and targeted molecular imaging products from the early research phase into clinical development. He also held the position of Global Head of Chemistry within GE Healthcare Medical Diagnostics. Dr Cuthbertson holds a BSc (Hons) from the University of Paisley and a PhD in Protein Chemistry from the University of Edinburgh, UK. He is a British citizen and currently resides in Norway.

As of 12 April 2013, Dr Cuthbertson holds no shares and 100,000 share options in Algeta.

Ms Dyvik joined Algeta in 2006 and has more than 20 years of pharmaceutical R&D, manufacturing and regulatory experience. Before joining Algeta, she held senior positions at Photocure ASA, a leading company focused on photodynamic therapy. At Photocure, Ms Dyvik was responsible for R&D and manufacturing of drug products, and acted as the Qualified Person for placing products on the market for Europe, also gaining substantial FDA experience in the USA. Earlier, Ms Dyvik worked in the development and management of new drug products at Nycomed ASA and Amersham Plc (now GE Healthcare). Ms Dyvik holds an MSc Pharm from the University of Oslo (1989). She is a Norwegian citizen and resides in Norway.

As of 12 April 2013, Ms Dyvik holds 20 shares and 238,962 share options in Algeta.

Dr Harrison joined Algeta in 2007 bringing more than two decades’ experience in business development and pharmaceutical licensing. During this time, he has been responsible for commercializing several innovative antibody therapeutics and NCEs, focusing particularly on important first-in-class oncology drugs. Before joining Algeta, Dr Harrison was Senior Vice President at the London-based FTSE 250 company BTG Plc, where he was responsible for establishing productive partnerships with a variety of major pharmaceutical and biotechnology companies. He oversaw the establishment of BTG’s international oncology strategic business and its global pharmaceutical licensing team. Earlier in his career, he spent ten years with Amersham Plc (now GE Healthcare) in research management in the US and UK. Dr Harrison received a PhD in Chemistry from the University of Manchester specializing in the field of novel oncology drugs. He is a British citizen and resides in the UK.

As of 12 April 2013, Dr Harrison holds no shares and 190,735 share options in Algeta.

Ms Løberg joined Algeta in 2002 and has more than 25 years of experience in the pharmaceutical sector. She has established and managed pharmaceutical quality systems in start-up biotech companies, and has a solid grounding in regulatory affairs, R&D and manufacturing of pharmaceutical products. She has acted as the Qualified Person in several pharmaceutical companies, for commercial pharmaceutical products as well as investigational medicinal products. From 1999 to 2002, she was Quality Director at Pronova Biocare AS, a world leader in the development and manufacture of omega-3 fatty acids for pharmaceutical, industrial, and consumer applications. In this role, Ms Løberg was responsible for all quality related matters, and her accomplishments included gaining FDA approval of a large manufacturing facility based in Norway. Ms Løberg has an MSc Pharm from the University of Oslo (1978). She is a Norwegian citizen and resides in Norway.

As of 12 April 2013, Ms Løberg holds 21,049 shares and 238,962 share options in Algeta.

Dr O’Bryan-Tear joined Algeta in 2009 as CMO having previously been a consultant to the Company on the clinical development of radium Ra 223 dichloride (radium 223) since 2004. He has more than 20 years of pharmaceutical industry experience in senior roles, managing and advising on the clinical development and registration of new drugs and vaccines. He has extensive development and clinical knowledge in oncology and has developed and successfully launched major oncology products. He has worked as both an independent consultant and in-house for a number of leading biotechnology and pharmaceutical companies. His former roles include: Vice President of Global Clinical R&D at GlaxoSmithKline Biologicals; Interim Medical Director at Genzyme UK; and Medical Director in the UK and Northern Europe for Bristol-Myers Squibb. Dr O’Bryan-Tear is a UK-trained physician who earned his MD at the Universities of Cambridge and London, and an MBA from Cranfield School of Management. He is a British citizen and resides in the UK.

As of 12 April 2013, Dr O’Bryan-Tear holds no shares and 303,750 share options in Algeta.

Mr Soug joined Algeta in 2008, bringing a wealth of financial, corporate development and M&A experience. Previously, he worked for six years at the Norwegian industrial group Orkla, the last three of which were as CFO of Orkla’s Russian arm, and before that within Orkla’s Corporate Development division focused on M&A. Mr Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. Mr Soug received an MSc in Economics and Financial Markets from Universität St Gallen in Switzerland in 1997. He is a Norwegian citizen and resides in Norway.

As of 12 April 2013, Mr Soug holds 17,200 shares and 200,628 share options in Algeta.